Panax notoginseng saponins alleviates metabolic dysfunction-associated steatotic liver disease in mice by influencing Nrf2/MT2
Frontiers in Pharmacology · 29.06.2026 · 17
DOI: 10.3389/fphar.2026.1874424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.06.2026. Verfasst von Lu Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Department of Henan Province, Education Department of Henan Province.
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic liver injury driven largely by oxidative stress. The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway plays a central role in antioxidant defense, and metallothionein-2 (MT2) is a potential downstream target. Panax notoginseng saponins (PNS) exhibit anti-inflammatory and antioxidant properties, but their effects on MASLD via Nrf2/MT2 signaling remain unclear. This study aimed to investigate whether PNS exerts protective effects against MASLD through Nrf2/MT2 signaling pathway.
Methods
Apolipoprotein E knockout mice were fed a high-fat diet (HFD) to establish MASLD model with PNS treatment. Hematoxylin and Eosin Staining (HE) and Oil Red O staining were conducted. Levels of triglyceride (TG), total cholesterol (TC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured. RNA sequencing was conducted, and expression of Nrf2, MT2 was measured. Molecular docking and surface plasmon resonance (SPR) assays were conducted to evaluate interactions between major saponins of PNS and MT2 protein.
Results
PNS alleviated lipid accumulation and liver injury in the MASLD model. PNS significantly alleviated oxidative stress and inflammation potentially through Nrf2/MT2 in MASLD mice. Molecular docking revealed that the five major saponins of PNS exhibited favorable binding affinities to MT2. SPR results further demonstrated that ginsenoside Rd may have the most stable binding conformation with MT2.
Conclusion
Our study demonstrates that PNS effectively reduces oxidative stress and inflammation in MASLD, potentially through Nrf2/MT2 pathway, and ginsenoside Rd exhibits favorable binding to MT2. These findings provide a novel pharmacological basis for the development of PNS as a potential therapeutic agent for MASLD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
- Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd., Wuzhou, China.
- Acupuncture and Massage College, Henan University of Chinese Medicine, Zhengzhou, China.
Förderung
- Science and Technology Department of Henan Province
- Education Department of Henan Province
Zitieren
APA
Liu, L., Bai, Y., Liu, X., Zhang, Y., Li, J., Wang, Y., Cao, X., Li, H., Wang, J., Tan, S., Wu, S., Wang, Y., Li, Y., & Miao, J. (2026). Panax notoginseng saponins alleviates metabolic dysfunction-associated steatotic liver disease in mice by influencing Nrf2/MT2. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1874424
Vancouver
Liu L, Bai Y, Liu X, Zhang Y, Li J, Wang Y, et al. Panax notoginseng saponins alleviates metabolic dysfunction-associated steatotic liver disease in mice by influencing Nrf2/MT2. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1874424
BibTeX
@article{Liu2026,
author = {Liu, Lu and Bai, Yifan and Liu, Ximeng and Zhang, Yiwen and Li, Jia and Wang, Yilin and Cao, Xinying and Li, Hanwei and Wang, Jun and Tan, Shushu and Wu, Shuihua and Wang, Yige and Li, Yilin and Miao, Jinxin},
title = {Panax notoginseng saponins alleviates metabolic dysfunction-associated steatotic liver disease in mice by influencing Nrf2/MT2},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1874424}
}
EUVIMED